BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 20222760)

  • 1. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
    Garofalo A; Goossens L; Lemoine A; Farce A; Arlot Y; Depreux P
    J Enzyme Inhib Med Chem; 2010 Apr; 25(2):158-71. PubMed ID: 20222760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
    Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
    Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
    Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
    Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
    Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
    Garofalo A; Goossens L; Six P; Lemoine A; Ravez S; Farce A; Depreux P
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2106-12. PubMed ID: 21353546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
    Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.
    Zhang HQ; Gong FH; Ye JQ; Zhang C; Yue XH; Li CG; Xu YG; Sun LP
    Eur J Med Chem; 2017 Jan; 125():245-254. PubMed ID: 27688180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents.
    Zheng QZ; Zhang F; Cheng K; Yang Y; Chen Y; Qian Y; Zhang HJ; Li HQ; Zhou CF; An SQ; Jiao QC; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(2):880-6. PubMed ID: 20005116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
    Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
    Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
    Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
    Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold.
    Chilin A; Conconi MT; Marzaro G; Guiotto A; Urbani L; Tonus F; Parnigotto P
    J Med Chem; 2010 Feb; 53(4):1862-6. PubMed ID: 20095624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
    Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
    Li Y; Tan C; Gao C; Zhang C; Luan X; Chen X; Liu H; Chen Y; Jiang Y
    Bioorg Med Chem; 2011 Aug; 19(15):4529-35. PubMed ID: 21724404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
    Garofalo A; Farce A; Ravez S; Lemoine A; Six P; Chavatte P; Goossens L; Depreux P
    J Med Chem; 2012 Feb; 55(3):1189-204. PubMed ID: 22229669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
    Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
    Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C
    Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, anticancer activity and docking of some substituted benzothiazoles as tyrosine kinase inhibitors.
    Bhuva HA; Kini SG
    J Mol Graph Model; 2010 Aug; 29(1):32-7. PubMed ID: 20493747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.